Evaluation of a new immunocastration vaccine for canines.
Researchers evaluated the efficacy and safety of a recombinant vaccine for dog immunocastration.
Two tests were done, one under controlled conditions and a second under field conditions. Animals were injected with 1 mL of 500 µg GnRXG/Q recombinant protein; 500 µg of low molecular weight chitosan as adjuvant; 1 mL NaCl 0.9% q.s.
In the first trial, eight Beagle male dogs between the ages of 1 and 3 comprised the sample, randomly divided into two groups: vaccinated group (n = 7) and control group (n = 2). The second trial involved 32 owned dogs.
The vaccine produced specific antibodies that remained until the end of the trial (day 270), inducing reduced testosterone and spermiogram changes in the immunized animals.
The vaccine also reduced sexual agonistic and marking behaviors.
Read more by clicking on the link below:
Reproductive and Behavioral Evaluation of a New Immunocastration Dog Vaccine
